Title:Long Non-coding RNA Therapeutics: Recent Advances and Challenges
Volume: 23
Issue: 16
Author(s): Anjali Sangeeth, Mahesh Malleswarapu, Amit Mishra and Ravi Kumar Gutti*
Affiliation:
- Department of Biochemistry, School of Life Sciences, University of Hyderabad, (PO) Gachibowli, Hyderabad 500046
(TS), India
Keywords:
miRNAs, lncRNAs, circRNAs, AML, CML, ribozyme.
Abstract: The discovery of the roles of RNA other than just as a messenger, such as a ribozyme,
and regulatory RNAs, such as microRNA and long noncoding RNAs, is fascinating. RNA is now
recognized as an important regulator involved in practically every biological process. Research in
the field of non-coding RNAs, specifically microRNAs (miRNAs) and long non-coding RNAs
(LncRNAs) have developed immensely over the years. Recent studies identified diverse RNAs, including
non-coding RNAs such as LncRNA and their various modes of action in the cells. These
RNAs are anticipated to be key targets for the treatment of various diseases since they control a
broad array of biological pathways. LncRNA-targeted drug platform delivers the pharmaceutical
industry a myriad of opportunities and has the potential to modulate diseases at the genetic level
while also overcoming the limitations of inconsistent proteins. This article focuses on the recent advancement
as well as the major challenges in the field and describes the various RNA-based therapeutics
that alter the quality of healthcare for many diseases and bring personalized medicines to
fruition. The article also summarizes RNA-based therapeutics that are undergoing testing in clinical
trials or have been granted FDA approval.